Business Context and Reporting Period
This Form 6-K filing contains the Half-Year Report for British American Tobacco p.l.c. (BAT) for the six-month period ended 30 June 2019. The report details the Group's financial performance, operational results, and strategic progress in transitioning toward Potentially Reduced-Risk Products (PRRP) amidst a declining global cigarette market.
Key Financial Metrics
| Metric | 2019 (Current Rates) | Change vs 2018 | 2019 (Constant Rates) |
|---|---|---|---|
| Revenue | £12,170m | +4.6% | £12,004m (+4.1%) |
| Profit from Operations | £4,380m | -1.3% | N/A |
| Adjusted Profit from Operations | £5,209m | +8.1% | £5,103m (+5.9%) |
| Operating Margin | 36.0% | -210 bps | N/A |
| Adjusted Operating Margin | 42.9% | +110 bps | N/A |
| Basic EPS | 123.2p | +4.6% | N/A |
| Adjusted Diluted EPS | 149.3p | +8.8% | 146.9p (+7.1%) |
| Net Cash from Operating Activities | £2,288m | -41% | N/A |
| Borrowings | £50,292m | +3.7% | N/A |
| Adjusted Net Debt | £45,532m | +1.8% | N/A |
Material Changes vs. Prior Period
- Volume Trends: Total cigarette and Tobacco Heating Product (THP) volume declined 3.5% to 336 billion sticks, in line with industry contraction. However, Strategic Cigarette and THP volume declined only 0.5%, gaining 60 basis points in volume share.
- New Categories Growth: Revenue from New Categories (THP, Vapour, Modern Oral) surged 31.3% to £548m.
- THP: Revenue up 8.5% to £313m; consumable volume up 17% to 3.9 billion sticks.
- Vapour: Revenue up 62.5% to £189m; volume up 32% to 102 million units.
- Modern Oral: Revenue up 274% to £46m; volume up 179% to 412 million pouches.
- Profitability Impact: Reported profit from operations fell 1.3% primarily due to a £436 million charge related to the Quebec Class Action in Canada. Excluding this and other adjusting items, adjusted profit grew 5.9% at constant rates.
- Cash Flow: Net cash generated from operating activities dropped 41% to £2,288m. This was driven by the timing of Master Settlement Agreement (MSA) payments in the US (which were paid in 2017 for the 2018 period) and working capital movements.
- Regional Performance:
- US: Revenue +10.2%, Profit +19.9%. Strong pricing and vapour growth offset volume declines.
- AMSSA: Reported profit fell 58.8% due to the Quebec charge; adjusted profit was flat (+0.8% at constant rates).
- ENA: Revenue flat (-0.5%); profit +1.9%.
Guidance, Outlook, and Risks
- Outlook: Management states the Group is "on track for a good year." The Strategic Portfolio continues to outperform the industry, driven by pricing power and the growth of New Categories.
- Dividends: The Board declared an interim dividend of 203.0p per share, payable in four quarterly installments of 50.75p. The second installment is due in August 2019.
- Key Risks and Contingencies:
- Quebec Class Action: A £436m charge was recognized. Imperial Tobacco Canada Ltd (ITCAN) has obtained protection under the Companies' Creditors Arrangement Act (CCAA), staying all tobacco litigation in Canada until at least October 2019.
- Russia Tax Audit: A preliminary audit report seeks £395m plus penalties for retrospective application of excise legislation (2015-2017). BAT treats this as a contingent liability and intends to object.
- Regulatory: Ongoing FDA scrutiny on youth usage of vapour products and potential menthol/nicotine reduction rules in the US. No material developments in rule-making were noted in H1 2019.
- UK Pension Fund: A "Buy-In" transaction was completed to match liabilities with insurance assets, reducing value at risk with no cash effect on the Group.
Investor Verification Checklist
- Quebec Litigation Status: Verify the timeline and potential outcomes of the CCAA stay and the broader Canadian tobacco litigation strategy.
- Russia Tax Dispute: Monitor the outcome of the objection to the £395m preliminary tax assessment.
- New Category Margins: Assess the sustainability of high growth in New Categories (Vapour/Modern Oral) and the impact of increased marketing investment on future margins.
- Cash Conversion: Review the normalization of cash flow in H2 2019 following the timing anomaly of MSA payments in H1.
- US Regulatory Environment: Track FDA decisions regarding Premarket Tobacco Product Applications (PMTA) and potential restrictions on menthol or nicotine levels.